Fetal Therapy & Interventions
The First Trimester Screening (FTS), conducted between 11 and 14 weeks of pregnancy, is a combined test that assesses the risk of the baby having chromosomal abnormalities, primarily Down syndrome (Trisomy 21) and Edwards Syndrome (Trisomy 18).
The First Trimester Screening (FTS), conducted between 11 and 14 weeks of pregnancy, is a combined test that assesses the risk of the baby having chromosomal abnormalities, primarily Down syndrome (Trisomy 21) and Edwards Syndrome (Trisomy 18).
The screening has two parts:
Genetic Sonogram (Ultrasound):This precisely measures the Nuchal Translucency (NT) , which is the clear fluid-filled space at the back of the fetal neck. An increased NT measurement is associated with a higher risk of chromosomal defects and major heart anomalies. The scan also confirms dating and viability.
Maternal Blood Test: This measures two placental proteins in the mother’s blood: PAPP-A (Pregnancy-Associated Plasma Protein-A) and Beta-hCG (human chorionic gonadotropin).5
The results from the sonogram, blood tests, and maternal age are integrated to calculate a personalized risk ratio. FTS is a highly effective screening test (not a diagnosis), and a high-risk result leads to a discussion about diagnostic options like CVS or Amniocentesis.
